NASDAQ:INO - Inovio Pharmaceuticals Stock Price, Forecast & News

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals's stock reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.26) by $0.01. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $2.72 million. Inovio Pharmaceuticals had a negative return on equity of 179.91% and a negative net margin of 1,809.64%. During the same period in the prior year, the business posted ($0.27) earnings per share. View Inovio Pharmaceuticals' Earnings History.

Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Inovio Pharmaceuticals.

7 equities research analysts have issued 12 month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $3.62 to $13.00. On average, they expect Inovio Pharmaceuticals' share price to reach $7.80 in the next year. This suggests a possible upside of 108.4% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.

Media coverage about INO stock has trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Inovio Pharmaceuticals.

Some companies that are related to Inovio Pharmaceuticals include Silk Road Medical (SILK), Atrion (ATRI), Tactile Systems Technology (TCMD), Shockwave Medical (SWAV), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Cryolife (CRY), Intersect ENT (XENT), Orthofix Medical (OFIX), MiMedx Group (MDXG), Cerus (CERS), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Sonoma Pharmaceuticals (SNOA), Opko Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), POET Technologies (POETF), WPX Energy (WPX), Micron Technology (MU), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

Inovio Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (4.98%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), ARK Investment Management LLC (4.58%), State Street Corp (1.56%), Geode Capital Management LLC (1.33%) and Jacobs Levy Equity Management Inc. (0.92%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

INO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., TIAA FSB, Bank of New York Mellon Corp, Defender Capital LLC., Bank of America Corp DE and Credit Suisse AG. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

INO stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ARK Investment Management LLC, Renaissance Technologies LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, UBS Group AG and Barclays PLC. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim and Laurent Humeau. View Insider Buying and Selling for Inovio Pharmaceuticals.

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INO stock can currently be purchased for approximately $3.75.

Inovio Pharmaceuticals has a market capitalization of $379.59 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.View Additional Information About Inovio Pharmaceuticals.

The official website for Inovio Pharmaceuticals is http://www.inovio.com/.

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]